Evotec presents a strategic roadmap towards precision medicine and confirms the objectives of the 2025 action plan during the day of the financial markets
- LAUNCH OF E.MPD, THE WORLD’S FIRST MOLECULAR PATIENT DATABASE
- DEPLOYMENT AND ACCELERATION OF PRECISION AI/ML TECHNOLOGIES TO INCREASE THE PROBABILITY OF SUCCESS (“POS”) IN RESEARCH, DEVELOPMENT AND MANUFACTURING
- EXPANSION OF EXECUTIVE COUNCIL WITH NEW CHIEF BUSINESS OFFICER (CBO) DR MATTHIAS EVERS AS AI/ML-DRIVEN PROCESS EXPERT
HAMBURG, GERMANY / ACCESSWIRE / March 2, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, NASDAQ: EVO) presents today at its Virtual Capital Markets Day how artificial intelligence (“AI”) and machine learning ( “ML”) have enabled the discovery and development of precision technologies processes increase the probability of success (“PoS”), i.e. an increasing rate of long-term approvals.
To leverage the power of molecular data, Evotec launches E.MPD, the company’s molecular patient database. E.MPD is one of the largest and highest quality molecular databases in the world.
Evotec’s integrated technology platforms show that the best way to effectively treat disease is to identify the underlying disease mechanisms and find the most appropriate therapy based on molecular data guiding all experimental processes towards a early relevance of the disease. Therefore, the aggregation, integration and accurate analysis of data is the critical path to efficient and affordable medicine in the future.
With E.MPD, Evotec is integrating another key offering into its Autobahn to Cures data-driven R&D. E.MPD will serve as the backbone of data-driven partnerships that will lead to innovative new medicines, better patient stratification, and potentially pave the way for a new paradigm of more effective diagnostic and preventive healthcare. Through the collection and analysis of patient-derived data in combination with AI/ML tools, Evotec is also able to better predict safety and efficacy metrics in drug development.
At its Virtual Capital Markets Day, Evotec outlines its unique business strategy to become the world’s leading precision medicine platform for the independent development of modalities for innovative therapeutic approaches. Based on partnerships, this strategy paves the way for an important co-ownership pipeline.
- Confirmation of Action Plan 2025 targets and progress update
- Examples of AI/ML-driven drug discovery and development processes resulting in multiple new partnerships, including the launch of several projects in the newly opened J.POD (R) modern biologics manufacturing facility in Redmond, WA (USA)
- New drug discovery platform and modality highlights (e.g. iPSC technologies, AI/ML-based safety prediction, E.INVENT-AI AI/ML-based integrated drug design and RNA technologies )
Dr. Werner Lanthaler, Managing Director of Evotec, said: “We are pleased to present some highlights and breakthroughs of the scientific power of our proprietary platforms today. The potential of our high-tech R&D platforms is enormous, just at the start, and fundamental for an accurate and affordable healthcare system of the future. Only by evoking probability of success (“PoS”) can we have a massive impact on returns on R&D investments and make more precise medicine accessible to all patients.”
In order to ensure the continuation of the growth observed in recent years and to further accelerate data-driven development, Evotec is adding a new member to the board of directors. Effective May 2, 2022, Dr. Matthias Evers will assume the position of Chief Commercial Officer. Currently, Dr. Evers is a Senior Partner and Global Co-Head of Life Sciences R&D at McKinsey & Company. A biochemist and bioinformatician by training, Matthias has developed innovation strategies for life science companies around the world, developed the functional capabilities necessary for sustainable productivity gains in research and development, and fostered collaboration between public partners. and private sector seeking accelerated impact on patients. As Chief Business Officer, Matthias will assume responsibility for business development, digital/technology and strategy.
Dr. Matthias Evers, Senior Partner at McKinsey, said “I’ve spent my career as a life science scientist and consultant harnessing the confluence of biology, chemistry and technology more broadly, i.e. data, AI/ ML as well as Automation Evotec’s platform is uniquely positioned – as can be seen in the iPSC space as an example – to capitalize on this opportunity as we enter a new era of science and understanding of After 20 years of impact consulting at McKinsey, I am thrilled to join the very strong team at Evotec to scale its platform globally and realize its ultimate promise for patients.”
“As a recognized thought leader in AI/ML-driven science innovation, Matthias will make an important contribution with his expertise and experience to our partner network”, added Dr. Werner Lanthaler, Managing Director of Evotec . “On behalf of our entire team and company, we look forward to working with Matthias and wish him a good start.”
About Virtual Capital Markets Day
Evotec will host its Virtual Capital Markets Day on March 2, 2022, starting at 8:00 a.m. EST (2:00 p.m. CET, 1:00 p.m. GMT). The meeting will take place via live webcast and a recording will be available at www.evotec.com.
ABOUT EVOTEC SE
Evotec is a life sciences company with a unique business model that pursues its mission to discover and develop highly effective treatments and bring them to patients. The Company’s multi-modality platform includes a unique combination of innovative technology, data and science for the discovery, development and production of first-class, first-class pharmaceuticals. Evotec leverages this “data-driven R&D Highway to Cure” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotech companies, academic institutions, as well as other health actors. Evotec has strategic activities in a wide range of currently underserved therapeutic areas, including neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world’s first pipeline of innovative co-owned therapeutics and has to date established a portfolio of over 200 proprietary and co-owned R&D projects, from early discovery to clinical development. Evotec operates worldwide with over 4,000 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary centers of excellence. For more information, visit www.evotec.com and follow us on Twitter @Evotec and LinkedIn .
This announcement contains forward-looking statements regarding future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “could”, “plan”, “potential”, “should”, “target”, ” ” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements include comments regarding the completion of the Offer. These forward-looking statements are based on currently available information and on expectations and assumptions that Evotec believed were reasonable at the time such statements were made. No assurance can be given that these expectations will prove to be correct. These statements involve known and unknown risks and are based on a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec’s control. Evotec expressly disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances about which any statement is based.
Evotec SE media contact:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, email@example.com
Evotec SE IR contact:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, firstname.lastname@example.org
THE SOURCE: Evotec SA
See the source version on accesswire.com: